Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046–60.

Article  CAS  PubMed  Google Scholar 

Van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397:410–27.

Article  PubMed  Google Scholar 

Shen YJ, Mishima Y, Shi J, Sklavenitis-Pistofidis R, Redd RA, Moschetta M, et al. Progression signature underlies clonal evolution and dissemination of multiple myeloma. Blood. 2021;137:2360–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020;395:132–41.

Article  CAS  PubMed  Google Scholar 

Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390:301–13.

Article  CAS  PubMed  Google Scholar 

Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495–505.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Minnie SA, Hill GR. Immunotherapy of multiple myeloma. J Clin Invest. 2020;130:1565–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Attwood MM, Fabbro D, Sokolov AV, Knapp S, Schiöth HB. Trends in kinase drug discovery: targets, indications and inhibitor design. Nat Rev Drug Discov. 2021;20:839–61.

Article  CAS  PubMed  Google Scholar 

Roskoski RJ. Properties of FDA-approved small molecule protein kinase inhibitors: a 2023 update. Pharmacol Res. 2023;187:106552.

Article  CAS  PubMed  Google Scholar 

Kung JE, Jura N. Prospects for pharmacological targeting of pseudokinases. Nat Rev Drug Discov. 2019;18:501–26.

CAS  PubMed  PubMed Central  Google Scholar 

Haikala HM, Lopez T, Köhler J, Eser PO, Xu M, Zeng Q, et al. EGFR inhibition enhances the cellular uptake and antitumor-activity of the HER3 antibody-drug conjugate HER3-DXd. Cancer Res. 2022;82:130–41.

Article  CAS  PubMed  Google Scholar 

Yang X, Cruz MI, Nguyen EV, Huang C, Schittenhelm RB, Luu J, et al. The pseudokinase NRBP1 activates Rac1/Cdc42 via P-Rex1 to drive oncogenic signalling in triple-negative breast cancer. Oncogene. 2023;42:833–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tabrizian N, Nouruzi S, Cui CJ, Kobelev M, Namekawa T, Lodhia I, et al. ASCL1 is activated downstream of the ROR2/CREB signaling pathway to support lineage plasticity in prostate cancer. Cell Rep. 2023;42:112937.

Article  CAS  PubMed  Google Scholar 

Arif A, Alameri AA, Tariq UB, Ansari SA, Sakr HI, Qasim MT, et al. The functions and molecular mechanisms of Tribbles homolog 3 (TRIB3) implicated in the pathophysiology of cancer. Int Immunopharmacol. 2023;114:109581.

Article  CAS  PubMed  Google Scholar 

Yu JM, Sun W, Wang ZH, Liang X, Hua F, Li K, et al. TRIB3 supports breast cancer stemness by suppressing FOXO1 degradation and enhancing SOX2 transcription. Nat Commun. 2019;10:5720.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shang S, Yang YW, Chen F, Yu L, Shen SH, Li K, et al. TRIB3 reduces CD8+ T cell infiltration and induces immune evasion by repressing the STAT1-CXCL10 axis in colorectal cancer. Sci Transl Med. 2022;14:eabf0992.

Article  CAS  PubMed  Google Scholar 

Hua F, Li K, Yu JJ, Lv XX, Yan J, Zhang XW, et al. TRB3 links insulin/IGF to tumour promotion by interacting with p62 and impeding autophagic/proteasomal degradations. Nat Commun. 2015;6:7951.

Article  CAS  PubMed  Google Scholar 

Ehteda A, Simon S, Franshaw L, Giorgi FM, Liu J, Joshi S, et al. Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG. Cell Rep. 2021;35:108994.

Article  CAS  PubMed  Google Scholar 

Falbo L, Raspelli E, Romeo F, Fiorani S, Pezzimenti F, Casagrande F, et al. SSRP1-mediated histone H1 eviction promotes replication origin assembly and accelerated development. Nat Commun. 2020;11:1345.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mo J, Liu F, Sun X, Huang H, Tan K, Zhao X, et al. Inhibition of the FACT complex targets aberrant hedgehog signaling and overcomes resistance to smoothened antagonists. Cancer Res. 2021;81:3105–20.

Article  CAS  PubMed  Google Scholar 

Gao Y, Li C, Wei L, Teng Y, Nakajima S, Chen X, et al. SSRP1 cooperates with PARP and XRCC1 to facilitate single-strand dna break repair by chromatin priming. Cancer Res. 2017;77:2674–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hossan T, Nagarajan S, Baumgart SJ, Xie W, Magallanes RT, Hernandez C, et al. Histone chaperone SSRP1 is essential for wnt signaling pathway activity during osteoblast differentiation. Stem Cells. 2016;34:1369–76.

Article  CAS  PubMed  Google Scholar 

Mo J, Tan K, Dong Y, Lu W, Liu F, Mei Y, et al. Therapeutic targeting the oncogenic driver EWSR1:FLI1 in Ewing sarcoma through inhibition of the FACT complex. Oncogene. 2023;42:11–25.

Article  CAS  PubMed  Google Scholar 

Martens S, Bridelance J, Roelandt R, Vandenabeele P, Takahashi N. MLKL in cancer: more than a necroptosis regulator. Cell Death Differ. 2021;28:1757–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K, et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 2007;109:1692–700.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fetisov TI, Borunova AA, Antipova AS, Antoshina EE, Trukhanova LS, Gorkova TG, et al. Targeting features of curaxin CBL0137 on hematological malignancies in vitro and in vivo. Biomedicines. 2023;11:230.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ohtake F, Saeki Y, Ishido S, Kanno J, Tanaka K. The K48-K63 branched ubiquitin chain regulates NF-κB signaling. Mol Cell. 2016;64:251–66.

Article  CAS  PubMed  Google Scholar 

Chen Q, Zheng W, Guan J, Liu H, Dan Y, Zhu L, et al. SOCS2-enhanced ubiquitination of SLC7A11 promotes ferroptosis and radiosensitization in hepatocellular carcinoma. Cell Death Differ. 2023;30:137–51.

Article  CAS  PubMed  Google Scholar 

Brisuda A, Ho JCS, Kandiyal PS, Ng JT, Ambite I, Butler DSC, et al. Bladder cancer therapy using a conformationally fluid tumoricidal peptide complex. Nat Commun. 2021;12:3427.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Park IS, Kim S, Yim Y, Park G, Choi J, Won C, et al. Multifunctional synthetic nano-chaperone for peptide folding and intracellular delivery. Nat Commun. 2022;13:4568.